Synovial Sarcoma Market Report and Forecast 2025-2034

Synovial Sarcoma Market Outlook

The synovial sarcoma market size is expected to grow at a CAGR of 4% during the forecast period of 2025-2034, driven by the increasing incidence of the disease along with rising technical advances to offer targeted therapies to patients.

Synovial Sarcoma Market Overview

Synovial sarcoma, also known as soft tissue sarcoma, is a rare cancer occurring in the connective tissues of the body. It usually affects the arms, legs, and belly. Symptoms include a painless lump in the hip, knee, ankle to shoulder. A sudden sharp pain along with swelling may also persist in patients. Synovial sarcoma is mostly slow growing and can be diagnosed via imaging tests, or biopsy.

In 2023, around 13,400  new soft tissue sarcomas are expected to be diagnosed in the United States. While 5,140 deaths (2,720 males and 2,420 females) are associated with the condition. It is more prevalent in adolescents and adults younger than 30 years of age, making it the third most commonly occurring in young adults and adolescents. The survival rate is approximately 50-60% at 5 years and 40-50% at 10 years. The ongoing advancements in oncology domain and monoclonal antibodies development are expected to improve the survival rates significantly.

Development in CAR T-cell Therapies for Personalized Treatment

To beat the rising mortalities associated with the condition, the synovial sarcoma market growth has been quite significant in recent years. In December 2023, Adaptimmune Therapeutics plc , a cancer therapy leader announced the submission of its Biologics License Application (BLA) to the FDA for afami-cel. Afami-cell is an investigational T-cell therapy intended to target melanoma-associated antigen (MAGE)-A4 and mesothelin, which has been supported by the positive data from SPEARHEAD-1 trial.

Advancements in Immunotherapy to Meet Synovial Sarcoma Market Demand

Immunotherapy has been a key area of investigation amongst researchers, owing to its ability to offer customized and effective treatment to patients. An October 2023 study published in Clinical Cancer Research revealed that immunotherapy with TB-1301  that targets NY-ESO-1-positive tumor cells showcased promising outcomes against recurrent synovial sarcoma. As per researchers, the efficacy and objective response rate was significantly better against pazopanib (Votrient) and other immunotherapy regimens. This indicates that the upcoming progressions in biotechnology and gene therapy are expected to build improved therapies.

Increased Research Activities to Identify Disease Prognosis

In July 2023, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) researchers, upon the molecular analysis of the tumor identified that a BRAF V600E  mutation was responsible for progression of relapsed disease. Such initiatives aimed at identifying the root cause of tumor progression at genetic level are expected to help the scientists come up with better therapeutic alternatives and lead to an increased synovial sarcoma market share in coming years.

Improvement in Existing Methods of Therapy

Over the years, medications such as doxorubicin, halaven and imatinib, along with radiotherapy have been used to shrink tumor size. This also helps in ensuring the accuracy in surgery. There have been high investments and research in developing new and effective medications, which are anticipated to increase the synovial sarcoma market size in the forecast period. Currently, Trabectedin, also known as Ecteinascidin-743 (ET-743) is administered to patients. TKI inhibitors such as Pazopanib are also considered effective.

Synovial Sarcoma Market Segmentation

Market Breakup by Diagnosis

• Imaging

• Biopsy

• Others

Market Breakup by Type

• ACXT-3102

• AL-3818

• Axitinib

• CMB-305

• CUE-102

• Others

Market Breakup by Treatment

• Surgery

• Anti-Angiogenesis Drugs

• Radiation Therapy

• Chemotherapy

Market Breakup by Distribution Channel

• Hospital Pharmacy

• Retail Pharmacy

• Others

Market Breakup by End User

• Hospital

• Clinics

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Synovial Sarcoma Market Regional Analysis

Europe, especially with a significant amount of geriatric population, holds high market value. The existence of several research and academic institutions plays a pivotal role in boosting market growth by offering novel treatments that showcase improved efficacy and reduced side effects. The increasing progression of clinical trials also impacts the market positively. The United States is anticipated to lead the synovial sarcoma market share owing to its well-equipped and technically advanced healthcare infrastructure. Several pharmaceutical companies are collaborating with advanced start-ups to leverage the latest techniques and devise quality treatment options to address the unmet needs of patients suffering from the disease.

The Asia Pacific, led by Japan is projected to experience a significant upswing in the synovial sarcoma market value. The growth can be credited to increasing healthcare investment in the region. Governments and organisations are also working on raising awareness via campaigns and programs to help the masses assess the early signs of the condition.

Synovial Sarcoma Market: Competitor Landscape

In November 2023, a clinical stage biotechnology firm Intensity Therapeutics, Inc . revealed that their lead proprietary investigational product candidate called INT230-6, alone or in combination with ipilimumab, was safe, tolerable, and effective in treating patients with relapsed, refractory, and metastatic sarcomas. The company using latest technologies such as the DfuseRxâ„  technology platform. This also indicates the trend of prominent companies deploying novel technologies to develop effective solutions for patients.

The key features of the synovial sarcoma market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• F. Hoffmann-La Roche Ltd

• Bayer AG

• Epizyme

• Bionpharma Cue Biopharma

• Eli Lilly and Company

• Adaptimmune Therapeutics Plc

• Advenchen Laboratories LLC

• EpiZyme Inc

• Merck & Co

• Immunocore Ltd

• Johnson & Johnson Private Limited

• Karyopharm Therapeutics Inc

• Novartis AG

• Pfizer Inc

• Takara Bio Inc

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report